1h Free Analyst Time
The cell and gene therapy market is poised to grow by $9.97 bn during 2022-2026, accelerating at a CAGR of 20.15% during the forecast period. The report on the cell and gene therapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of chronic diseases, the increase in special drug designations, and increasing funding for cell and gene-based research.
The cell and gene therapy market analysis includes type segment and geographic landscape.
The cell and gene therapy market is segmented as below:
By Type
- Cell therapy
- Gene therapy
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the cell and gene therapy market covers the following areas:
- Cell and gene therapy market sizing
- Cell and gene therapy market forecast
- Cell and gene therapy market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global cell and gene therapy market: Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., bluebird bio Inc., Bristol Myers Squibb Co., Castle Creek Biosciences Inc., CORESTEM Inc., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC., Ferring BV, Gilead Sciences Inc., Helixmith Co. Ltd., Human Stem Cells Institute, JCR Pharmaceuticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, Orchard Therapeutics Plc, Pfizer Inc., Sibiono GeneTech Co. Ltd., and Vericel Corp.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is increasing focus on the development of drugs for emerging applications.`
According to the report, one of the major drivers for this market is the increasing prevalence of chronic diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alnylam Pharmaceuticals Inc.
- Amgen Inc.
- Biogen Inc.
- bluebird bio Inc.
- Bristol Myers Squibb Co.
- Castle Creek Biosciences Inc.
- CORESTEM Inc.
- Cytori Therapeutics Inc.
- Dendreon Pharmaceuticals LLC.
- Ferring BV
- Gilead Sciences Inc.
- Helixmith Co. Ltd.
- Human Stem Cells Institute
- JCR Pharmaceticals Co. Ltd.
- Kolon TissueGene Inc.
- Novartis AG
- Orchard Therapeutics Plc
- Pfizer Inc.
- Sibiono GeneTech Co. Ltd.
- Vericel Corp.
